medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2022, Número 3

<< Anterior Siguiente >>

Medicina & Laboratorio 2022; 26 (3)


Reacciones de hipersensibilidad a alglucosidasa alfa en enfermedad de Pompe: dos casos de desensibilización exitosa

Ortiz-Giraldo B, Santamaría-Salazar LC, Mopán-Tique JM

Idioma: Español
Referencias bibliográficas: 26
Paginas: 287-296
Archivo PDF: 91.24 Kb.


RESUMEN

La enfermedad de Pompe es un desorden neuromuscular autosómico recesivo de baja prevalencia, causado por la deficiencia total o parcial de la enzima alfa glucosidasa ácida (GAA), cuya única terapia de reemplazo enzimático disponible es la alglucosidasa alfa recombinante. Las reacciones adversas asociadas a la infusión se presentan con frecuencia. Se reportan dos casos de desensibilización exitosa con alglucosidasa alfa utilizando protocolos con dosis meta de 20 mg/kg, administrados quincenalmente; el primero de ellos, en una niña con historia de reacción adversa grave a los 15 meses de edad, en quien se utilizó un esquema con una dilución inicial de 1/10.000.000 de 28 pasos y una duración total de 13,1 horas. En el segundo caso, la paciente tuvo una reacción adversa grave a los 4 años de edad, se utilizó el protocolo de 22 pasos, concentración inicial de 1/1.000.000 y duración total de 7,2 horas. Se concluye que en pacientes con enfermedad de Pompe que presentan reacciones adversas durante la terapia de reemplazo enzimático, es posible realizar la desensibilización cada dos semanas con la dosis estándar de 20 mg/kg de forma exitosa, y progresivamente lograr la administración usual de la infusión.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Taverna S, Cammarata G, Colomba P, SciarrinoS, Zizzo C, Francofonte D, et al. Pompedisease: pathogenesis, molecular genetics anddiagnosis. Aging (Albany NY) 2020;12:15856-15874. https://doi.org/10.18632/aging.103794.

  2. Martiniuk F, Chen A, Mack A, ArvanitopoulosE, Chen Y, Rom WN, et al. Carrier frequencyfor glycogen storage disease type IIin New York and estimates of affected individualsborn with the disease. Am J Med Genet1998;79:69-72. https://doi.org/10.1002/(sici)1096-8628(19980827)79:1<69::aidajmg16>

  3. 3.0.co;2-k.3. Lipinski SE, Lipinski MJ, Burnette A, Platts-Mills TA, Wilson WG. Desensitization of anadult patient with Pompe disease and a historyof anaphylaxis to alglucosidase alfa. MolGenet Metab 2009;98:319-321. https://doi.org/10.1016/j.ymgme.2009.07.001.

  4. Meena NK, Raben N. Pompe disease: New developmentsin an old lysosomal storage disorder.Biomolecules 2020;10:1339. https://doi.org/10.3390/biom10091339.

  5. Kohler L, Puertollano R, Raben N. Pompedisease: From basic science to therapy. Neurotherapeutics2018;15:928-942. https://doi.org/10.1007/s13311-018-0655-y.

  6. Chen M, Zhang L, Quan S. Enzyme replacementtherapy for infantile-onset Pompe disease. CochraneDatabase Syst Rev 2017;11:Cd011539.https://doi.org/10.1002/14651858.CD011539.pub2.

  7. Kishnani PS, Corzo D, Leslie ND, GruskinD, Van der Ploeg A, Clancy JP, et al. Earlytreatment with alglucosidase alpha prolongslong-term survival of infants with Pompe disease.Pediatric research 2009;66:329-335. https://doi.org/10.1203/PDR.0b013e3181b24e94.

  8. Banugaria SG, Prater SN, Ng YK, KoboriJA, Finkel RS, Ladda RL, et al. The impact ofantibodies on clinical outcomes in diseasestreated with therapeutic protein: lessons learnedfrom infantile Pompe disease. Genet Med2011;13:729-736. https://doi.org/10.1097/GIM.0b013e3182174703.

  9. Kishnani PS, Goldenberg PC, DeArmey SL,Heller J, Benjamin D, Young S, et al. Crossreactiveimmunologic material status affectstreatment outcomes in Pompe disease infants.Mol Genet Metab Rep 2010;99:26-33. https://doi.org/10.1016/j.ymgme.2009.08.003.

  10. Karimian Z, Whitley CB, Rudser KD, Utz JRJ.Delayed infusion reactions to enzyme replacementtherapies. JIMD Rep 2017;34:63-70.https://doi.org/10.1007/8904_2016_8.

  11. Turgay-Yagmur I, Unal-Uzun O, Kucukcongar-Yavas A, Kulhas-Celik I, Toyran M, Gunduz M,et al. Management of hypersensitivity reactionsto enzyme replacement therapy in children withlysosomal storage diseases. Ann Allergy AsthmaImmunol 2020;125:460-467. https://doi.org/10.1016/j.anai.2020.07.010.

  12. Aranda CS, Ensina LF, Nunes IC, Mallozi MC,Mendes C, Martins AM, et al. Diagnosis andmanagement of infusion-related hypersensitivityreactions to enzyme replacement therapy forlysosomal diseases: The role of desensitization.J Allergy Clin Immunol Pract 2016;4:354-356.https://doi.org/10.1016/j.jaip.2015.11.012.

  13. Castells M. Rapid desensitization for hypersensitivityreactions to medications. Immunol AllergyClin North Am 2009;29:585-606. https://doi.org/10.1016/j.iac.2009.04.012.

  14. Kuehn BM. New treatment approved foradults and children with pompe disease.JAMA 2021;326:1000. https://doi.org/10.1001/jama.2021.15588.

  15. Zhu Y, Jiang JL, Gumlaw NK, Zhang J, BercurySD, Ziegler RJ, et al. Glycoengineeredacid alpha-glucosidase with improved efficacyat correcting the metabolic aberrations andmotor function deficits in a mouse model ofPompe disease. Mol Ther 2009;17:954-963.https://doi.org/10.1038/mt.2009.37.

  16. Diaz-Manera J, Kishnani PS, Kushlaf H, LadhaS, Mozaffar T, Straub V, et al. Safety and efficacyof avalglucosidase alfa versus alglucosidasealfa in patients with late-onset Pompe disease(COMET): a phase 3, randomised, multicentretrial. Lancet Neurol 2021;20:1012-1026. https://doi.org/10.1016/s1474-4422(21)00241-6.

  17. Baruteau J, Broomfield A, Crook V, FinneganN, Harvey K, Burke D, et al. Successful desensitisationin a patient with CRIM-positive infantile-onset pompe disease. JIMD rep 2014;12:99-102. https://doi.org/10.1007/8904_2013_250.

  18. El-Gharbawy AH, Mackey J, DeArmey S,Westby G, Grinnell SG, Malovrh P, et al. Anindividually, modified approach to desensitizeinfants and young children with Pompe disease,and significant reactions to alglucosidase alfainfusions. Mol Genet Metab 2011;104:118-122.https://doi.org/10.1016/j.ymgme.2011.07.004.

  19. Karagol IH, Bakirtas A, Yilmaz O, Topal E, KucukcongarA, Ezgu FS, et al. Desensitisationof the youngest patient with Pompe disease inresponse to alglucosidase alfa. Allergol Immunopathol(Madr) 2014;42:372-375. https://doi.org/10.1016/j.aller.2013.02.012.

  20. Capanoglu M, Dibek Misirlioglu E, AzkurD, Vezir E, Guvenir H, Gunduz M, et al. IgEmediatedhypersensitivity and desensitisationwith recombinant enzymes in Pompe diseaseand type I and type VI mucopolysaccharidosis.Int Arch Allergy Immunol 2016;169:198-202.https://doi.org/10.1159/000446154.

  21. Gragnaniello V, Fecarotta S, Pecoraro A, TaralloA, Catzola A, Spadaro G, et al. Desensitizationof two young patients with infantile-onsetPompe disease and severe reactions to alglucosidasealfa. Neurol Sci 2019;40:1453-1455.https://doi.org/10.1007/s10072-019-03744-3.

  22. Toh TSW, Chong KW, Goh AEN, Goh JCY,Ting TW, Tan ES, et al. Enzyme replacementtherapy desensitization in a child with infantileonset Pompe disease. Asian Pac J AllergyImmunol 2020. [Epub ahead of print] 16 defebrero de 2020. https://doi.org/10.12932/ap-060919-0638.

  23. Cernadas JR, Brockow K, Romano A, AbererW, Torres MJ, Bircher A, et al. General considerationson rapid desensitization for drug hypersensitivity- a consensus statement. Allergy2010;65:1357-1366. https://doi.org/10.1111/j.1398-9995.2010.02441.x.

  24. Gallay L, Petiot P, Durieu I, StreichenbergerN, Berard F. SWORD: A simplified desensitizationprotocol for enzyme replacement therapyin adult Pompe disease. Neuromuscul Disord2016;26:801-804. https://doi.org/10.1016/j.nmd.2016.07.006.

  25. Cianferoni A. Non-IgE-mediated anaphylaxis.J Allergy Clin Immunol 2021;147:1123-1131.https://doi.org/10.1016/j.jaci.2021.02.012.

  26. Desai AK, Li C, Rosenberg AS, Kishnani PS.Immunological challenges and approachesto immunomodulation in Pompe disease: a literaturereview. Ann Transl Med 2019;7:285.https://doi.org/10.21037/atm.2019.05.27.




2020     |     www.medigraphic.com